Undervalued Criteria in the Evaluation of Multimodal Trials for Upper GI Cancers

Cancer Invest. 2014 Dec;32(10):497-506. doi: 10.3109/07357907.2014.958497. Epub 2014 Sep 24.

Abstract

Global economies and their health systems face a huge challenge from cancer: 1 in 3 women and 1 in 2 men will develop cancer in their lifetime. In the less developed countries, the volume of cancer patients will overwhelm the existing healthcare systems. Even in developed regions, patients with upper gastrointestinal (GI) cancer usually present with locally advanced tumors that their prognosis is poor. A detailed knowledge of anatomy, embryology, epidemiology, tumor classifications and tumor growth is key understanding and evaluating the relevant research. We review undervalued criteria necessary to evaluate the response to multimodal therapy for upper GI cancers.

Keywords: Anticancer therapy; Esophageal carcinoma; Multimodal therapy; Neoadjuvant therapy; Upper gastrointestinal tract.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy
  • Clinical Trials as Topic
  • Combined Modality Therapy / methods
  • Esophageal Neoplasms / epidemiology
  • Esophageal Neoplasms / pathology*
  • Esophageal Neoplasms / therapy*
  • Female
  • Humans
  • Male
  • Prognosis
  • Stomach Neoplasms / epidemiology
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / therapy*